OBJECTIVE: To determine the prevalence of Lynch syndrome mutations in a Canadian hereditary cancer clinic population, and to determine the effectiveness of the program's referral criteria and testing algorithm. METHODS: A retrospective chart review of all patients who were referred for and received genetic counselling at the BC Cancer Agency's Hereditary Cancer Program for a family history of colon cancer from August 1, 2004, to September 1, 2006, was performed. Charts were reviewed for referral criteria met, cancer history, whether testing was offered and the outcome of testing. RESULTS: Lynch syndrome was confirmed or highly suspected in 14.3% of index test patients (eight of 56) by the identification of a deleterious mutation or variant likely to be deleterious in either of the hMLH1 or hMSH2 mismatch repair genes. In the program, the two most effective criteria were a personal diagnosis of two or more primary Lynch syndrome-related cancers (one diagnosed at younger than 50 years of age) or two first-degree relatives with a Lynch syndrome-related cancer (both diagnosed at younger than 50 years of age). The respective positive predictive values of these two criteria were calculated to be 66.7% (95% CI 40% to 93%) and 58.3% (95% CI 30.4% to 86.2%). CONCLUSIONS: The Hereditary Cancer Program developed and successfully implemented an approach that selected individuals at risk for Lynch syndrome with a significant pretest probability of mutation of 14.3%. Improved ascertainment of families with Lynch syndrome will require greater physician awareness of referral criteria, program advances in the testing algorithm and a population-based approach to screening incident colon cancers.
OBJECTIVE: To determine the prevalence of Lynch syndrome mutations in a Canadian hereditary cancer clinic population, and to determine the effectiveness of the program's referral criteria and testing algorithm. METHODS: A retrospective chart review of all patients who were referred for and received genetic counselling at the BC Cancer Agency's Hereditary Cancer Program for a family history of colon cancer from August 1, 2004, to September 1, 2006, was performed. Charts were reviewed for referral criteria met, cancer history, whether testing was offered and the outcome of testing. RESULTS:Lynch syndrome was confirmed or highly suspected in 14.3% of index test patients (eight of 56) by the identification of a deleterious mutation or variant likely to be deleterious in either of the hMLH1 or hMSH2 mismatch repair genes. In the program, the two most effective criteria were a personal diagnosis of two or more primary Lynch syndrome-related cancers (one diagnosed at younger than 50 years of age) or two first-degree relatives with a Lynch syndrome-related cancer (both diagnosed at younger than 50 years of age). The respective positive predictive values of these two criteria were calculated to be 66.7% (95% CI 40% to 93%) and 58.3% (95% CI 30.4% to 86.2%). CONCLUSIONS: The Hereditary Cancer Program developed and successfully implemented an approach that selected individuals at risk for Lynch syndrome with a significant pretest probability of mutation of 14.3%. Improved ascertainment of families with Lynch syndrome will require greater physician awareness of referral criteria, program advances in the testing algorithm and a population-based approach to screening incident colon cancers.
Authors: C E Bronner; S M Baker; P T Morrison; G Warren; L G Smith; M K Lescoe; M Kane; C Earabino; J Lipford; A Lindblom Journal: Nature Date: 1994-03-17 Impact factor: 49.962
Authors: Asad Umar; C Richard Boland; Jonathan P Terdiman; Sapna Syngal; Albert de la Chapelle; Josef Rüschoff; Richard Fishel; Noralane M Lindor; Lawrence J Burgart; Richard Hamelin; Stanley R Hamilton; Robert A Hiatt; Jeremy Jass; Annika Lindblom; Henry T Lynch; Païvi Peltomaki; Scott D Ramsey; Miguel A Rodriguez-Bigas; Hans F A Vasen; Ernest T Hawk; J Carl Barrett; Andrew N Freedman; Sudhir Srivastava Journal: J Natl Cancer Inst Date: 2004-02-18 Impact factor: 13.506
Authors: Chris D Bajdik; Steve Sung; John J Spinelli; David Huntsman; Steven Gallinger; Douglas Horsman; Richard P Gallagher Journal: Genet Test Date: 2007
Authors: W Kievit; J H F M de Bruin; E M M Adang; M J L Ligtenberg; F M Nagengast; J H J M van Krieken; N Hoogerbrugge Journal: Clin Genet Date: 2004-04 Impact factor: 4.438
Authors: L A Aaltonen; P Peltomäki; J P Mecklin; H Järvinen; J R Jass; J S Green; H T Lynch; P Watson; G Tallqvist; M Juhola Journal: Cancer Res Date: 1994-04-01 Impact factor: 12.701
Authors: Anja Wagner; Alicia Barrows; Juul Th Wijnen; Heleen van der Klift; Patrick F Franken; Paul Verkuijlen; Hidewaki Nakagawa; Marjan Geugien; Shantie Jaghmohan-Changur; Cor Breukel; Hanne Meijers-Heijboer; Hans Morreau; Marjo van Puijenbroek; John Burn; Stephany Coronel; Yulia Kinarski; Ross Okimoto; Patrice Watson; Jane F Lynch; Albert de la Chapelle; Henry T Lynch; Riccardo Fodde Journal: Am J Hum Genet Date: 2003-03-25 Impact factor: 11.025
Authors: J C Carroll; S Blaine; J Permaul; E Dicks; E Warner; M J Esplen; H Rothenmund; K Semotiuk; G Worrall; J McLaughlin Journal: J Community Genet Date: 2014-04-09